Monte Rosa Therapeutics, Inc. (GLUE) Investor Relations Documents

Monte Rosa Therapeutics, Inc. (GLUE) investor relations documents from the company's IR site: 10 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-06	Press release	Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
2026-07-02	Press release	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-02	Press release	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-20	Press release	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
2026-05-07	Press release	Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
2026-05-05	Press release	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-20	Press release	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026
2026-03-17	Press release	Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
2026-03-16	Press release	Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination
2026-02-24	Press release	Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide

GLUE overview · GLUE earnings · GLUE financials · GLUE KPIs · GLUE ownership · GLUE peers · GLUE filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.